Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients

BMC Nephrology

Nobukazu Ishizaka¹  Masaaki Hoshiga¹  Koichi Sohmiya¹  Hideaki Morita¹  Shun Kizawa¹  Shu-ichi Fujita¹  Michishige Ozeki¹ 

[1] Department of Cardiology, Osaka Medical College, Takatsuki-shi Daigaku-machi 2–7, Osaka 569-8686, Japan

关键词: Chronic kidney disease;    Klotho;    Fibroblast growth factor-23;   

Others  :  1082624
DOI  :  10.1186/1471-2369-15-147

 received in 2014-05-12, accepted in 2014-09-03,  发布年份 2014

【 摘 要 】

Background

Expression and/or excretion of fibroblast growth factor-23 (FGF23) and its co-receptor Klotho are altered in patients with end-stage renal disease. The possibility that the FGF23/α-Klotho system mediates the aggravated cardiovascular outcome among patients with chronic kidney disease (CKD) has been suggested. We determined whether FGF23 and α-Klotho concentrations are altered among patients with reduced renal function and proteinuria.

Methods

Serum FGF23 and α-Klotho were measured in cardiology patients who were not undergoing chronic hemodialysis. Estimated glomerular filtration rate (eGFR) was correlated negatively with FGF23 and positively with α-Klotho.

Results

The correlation between FGF23 and the renal tubular maximum reabsorption rate of phosphate to the GFR (TmP/GFR) was not significant, but that between FGF23 and serum calcium or inorganic phosphate was significant among patients with an estimated GFR of less than 60 mL/min/m². By stepwise multivariate regression analysis, eGFR was selected as significant predictor for FGF23 or α-Klotho among patients with an estimated GFR of less than 60 mL/min/m²; however, urine albumin/creatinine ratio was not selected as a predictor for FGF23 or α-Klotho irrespective of the eGFR levels. In patients with eGFR of <60 mL/min/1.73 m², UACR was significantly associated with log(FGF23); but, this association did not remain statistically significant in a multivariate model.

Conclusions

Among cardiology patients with various stages of CKD, serum concentrations of FGF23 and α-Klotho were associated with renal function, but not with the extent of proteinuria.

【 授权许可】

   
2014 Ozeki et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26(3):345-348.
• [2]Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98(11):6500-6505.
• [3]Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI, Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, et al.: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390(6655):45-51.
• [4]Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH: Circulating alpha-klotho levels in CKD and relationship to progression. Am J Kidney Dis 2013, 61(6):899-909.
• [5]Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y: Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001, 280(4):1015-1020.
• [6]Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, Iwamoto N, Kurumatani N, Iwano M, Nabeshima Y, Konishi N, Saito Y: Reduced renal alpha-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One 2014, 9(1):e86301.
• [7]Martin A, David V, Quarles LD: Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012, 92(1):131-155.
• [8]Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119(19):2545-2552.
• [9]Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, et al.: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121(11):4393-4408.
• [10]Navarro-Gonzalez JF, Donate-Correa J, Muros De Fuentes M, Perez-Hernandez H, Martinez-Sanz R, Mora-Fernandez C: Reduced Klotho is associated with the presence and severity of coronary artery disease. Heart 2014, 100(1):34-40.
• [11]Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG, Chronic Renal Insufficiency Cohort (CRIC) Study Group: Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012, 23(10):1725-1734.
• [12]Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N: Association between circulating fibroblast growth factor 23, alpha-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One 2013, 8(9):e73184.
• [13]Fujita S, Okamoto Y, Shibata K, Morita H, Ito T, Sohmiya K, Hoshiga M, Ishizaka N: Serum uric Acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients. PLoS One 2013, 8(12):e82735.
• [14]Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012, 82(7):737-747.
• [15]Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003, 18(7):1227-1234.
• [16]Urena Torres P, Friedlander G, De Vernejoul MC, Silve C, Prie D: Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008, 73(1):102-107.
• [17]Yokoyama K, Imura A, Ohkido I, Maruyama Y, Yamazaki Y, Hasegawa H, Urae J, Sekino H, Nabeshima Y, Hosoya T: Serum soluble alpha-klotho in hemodialysis patients. Clin Nephrol 2012, 77(5):347-351.
• [18]Mathew J, Katz R, St John Sutton M, Dixit S, Gerstenfeld EP, Ghio S, Gold MR, Linde C, Shlipak MG, Deo R: Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail 2012, 14(12):1420-1428.
• [19]Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB: Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003, 26(10):2764-2769.
• [20]Liu JJ, Liu S, Morgenthaler NG, Wong MD, Tavintharan S, Sum CF, Lim SC: Association of plasma soluble alpha-klotho with pro-endothelin-1 in patients with type 2 diabetes. Atherosclerosis 2014, 233(2):415-418.
• [21]Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53(6):982-992.
• [22]Kenny AP, Glen AC: Tests of phosphate reabsorption. Lancet 1973, 2(7821):158.
• [23]Chong WH, Molinolo AA, Chen CC, Collins MT: Tumor-induced osteomalacia. Endocr Relat Cancer 2011, 18(3):R53-R77.
• [24]Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
• [25]Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Astor BC: Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2012, 60(2):207-216.
• [26]McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG: Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant 2011, 26(3):933-938.
• [27]Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE: FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 2012, 7(5):727-734.
• [28]Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, Nakamura Y, Sato M, Nangaku M, Hirata Y, Nagai R: In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002, 39(4):838-843.
• [29]Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C: Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One 2013, 8(8):e70775.
• [30]Kacso IM, Bondor CI, Kacso G: Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin Biochem 2012, 45(16–17):1415-1420.
• [31]Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB: The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009, 20(11):2380-2388.
• [32]Lim SC, Liu JJ, Subramaniam T, Sum CF: Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst 2013. doi:10.1177/1470320313475905
• [33]Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L: Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clin J Am Soc Nephrol 2013, 8(11):1899-1905.
• [34]Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D: Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone 2014, 66C:8-14.
• [35]Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004, 145(11):5269-5279.
• [36]Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004, 314(2):409-414.
• [37]Ogura E, Kageyama K, Fukumoto S, Yagihashi N, Fukuda Y, Kikuchi T, Masuda M, Suda T: Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. Intern Med 2008, 47(7):637-641.
• [38]Komo T: Relation between serum FGF-23 and phosphate or bone metabolism in adults. J Osaka City Med Association 2007, 56:35-41. [In Japanese]
• [39]Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL: Soluble klotho and autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012, 7(2):248-257.
• [40]Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, Serra AL, Wagner CA: Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int 2014, 85(6):1340-1350.
• [41]Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014, 25(2):349-360.
• [42]Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, Fliser D, Heine GH: Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2–4. Clin J Am Soc Nephrol 2014, 9(6):1049-1058.